Prescription Tadalafil tablets recalled for manufacturing process deviations
Preferred Pharmaceuticals is recalling 32 bottles of Tadalafil 20 mg tablets due to manufacturing process deviations identified during FDA inspection. The recalled lots expire January 31, 2024.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall for manufacturing process deviations without reported illnesses or injuries. No specific contamination or defect is identified, classifying this as a precautionary recall.
Plain-English summary
Preferred Pharmaceuticals, Inc. is recalling 32 bottles of Tadalafil 20 mg tablets distributed nationwide. The affected lots are C0822E, F1121B, and G2721L, all with an expiration date of January 31, 2024.
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations discovered at the manufacturing facility (Accord Healthcare) following an FDA inspection. cGMP compliance ensures the safety, purity, and quality of pharmaceutical products. The specific nature of the manufacturing deviations is not detailed in the recall notice.
Patients currently taking this medication should not stop without consulting their healthcare provider. Individuals with affected lots should contact their pharmacy or doctor to determine if their supply is involved and to arrange an alternative source if needed.
For more information, consumers may contact the FDA's division of drug safety or speak with their healthcare provider or pharmacist.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug
- Affected units
- 32
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lot: C0822E
- Exp 1/31/2024
- F1121B
- G2721L
- Exp 1/31/2024.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 17 recalled by Preferred Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 17 products in this recall →Related recalls
Same brand · TADALAFIL
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- HighTadalafil tablets recalled for manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
- HighFDA Recalls Tadalafil Tablets Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
- HighDuloxetine Delayed-Release Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2024-05-29
Same hazard · manufacturing deviation
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateiVIZIA Dry Eye Lubricant Drops Recalled for Sterility Assurance
FDA (Drugs) · 2026-05-06
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29